Patent intelligence · US
US 10000456
Polycyclic compounds as lysophosphatidic acid receptor antagonists
Polycyclic compounds as lysophosphatidic acid receptor antagonists
Patent details — US 10000456
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 19, 2018
- Expiration
- Jun 14, 2038
- Applicant
- AMIRA PHARMACEUTICALS, INC.
- Claims
- 13
- CPC classes
- A61P, A61P1/00, A61P1/16, A61P11/00
Quick answer
US 10000456 (Polycyclic compounds as lysophosphatidic acid receptor antagonists) is held by AMIRA PHARMACEUTICALS, INC.. Status: granted. Granted Jun 19, 2018. Expires Jun 14, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AMIRA PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61P, A61P1/00, A61P1/16, A61P11/00, A61P11/06, A61P13/00
More from AMIRA PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 10000456?
US 10000456 (Polycyclic compounds as lysophosphatidic acid receptor antagonists) is held by AMIRA PHARMACEUTICALS, INC.. Status: granted. Granted Jun 19, 2018. Expires Jun 14, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10000456?
AMIRA PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 10000456 expire?
Our index shows an expiration date of Jun 14, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.